Table 1.
Clinical and demographic characteristics.
| Subject ID | Age (yrs) | Sex | Disease duration (yrs) | PD medications (type, dose) | (MDS)-UPDRS-III |
|---|---|---|---|---|---|
| 1 | 62 | M | 4 | Pram (4.5 mg), Ras (1 mg) | 22 |
| 2 | 70 | M | – | Pram (1.5 mg), CD/LD (25/100 mg) | 17 |
| 3 | 52 | M | 9 | CD/LD, Rop | 62 |
| 4 | 61 | M | – | Rop (1 mg) | 15 |
| 5 | 60 | M | 1 | Rop (1 mg) | 27 |
| 6 | 72 | F | 9 | Rop | 13 |
| 7 | 64 | F | 8 | Ras (1 mg) CD/LD (25/100 mg) | 34 |
| 8 | 67 | M | 3 | CD/LD (25/100 mg) | 23 |
| 9 | 69 | M | – | CD/LD (50/200 mg) | 52 |
| 10 | 69 | M | – | CD/LD | 37 |
| 11 | 52 | M | 6 | Rop (8 mg) | 14 |
| 12 | 64 | M | 7 | CD/LD (25/100 mg), Aman | 28 |
| 13 | 75 | M | 8 | CD/LD (25/100 mg) | 29 |
| 14 | 64 | M | 7 | CD/LD (10/100 mg), Rot (8 mg) | 53 |
| 15 | 61 | M | 8 | CD/LD (25/100 mg), Pram (1.5 mg), Sel (2 mg) | 35 |
| 16 | 55 | M | 6 | CD/LD (25/100 mg) | 21 |
| 17 | 78 | F | 16 | CD/LD (25/100 mg) | 36 |
| 18 | 73 | M | 8 | CD/LD (25/100 mg), Rot (4 mg) | 54 |
| 19 | 55 | M | 9 | Pram (1 mg), CD/LD (25/100 mg), Sel (5 mg) | 60 |
| 20 | 66 | M | 5 | Rop (3 mg), Ras (1 mg) | 40 |
| 21 | 61 | M | 3 | CD/LD (25/100 mg), Pram (1 mg) | 57 |
| 22 | 67 | M | 5 | CD/LD (25/100 mg) | 36 |
| 23 | 72 | M | 8 | CD/LD (25/100 mg) | 39 |
| 24a | 54 | F | 6 | Pram (4.5 mg), CD/LD (25/100 mg) | 27 |
| 25a | 76 | M | 4 | Ras (1 mg), CD/LD (50/200 mg) | 35 |
| 26a | 57 | M | 3 | Aman (100 mg), CD/LD (25/100 mg) | 31 |
| 27a | 75 | M | – | Pram (0.5 mg), CD/LD (25/100 mg) | 17 |
Notes: Pram = pramipexole; Ras = rasagiline; CD/LD = carbidopa/levodopa; Rop = ropinirole; Aman = amantadine; Sel = selegiline; Rot = rotigotine.
a
Excluded from analysis.